Serán Bioscience, a leading contract development and manufacturing organization (CDMO) providing a comprehensive suite of development, analytical and manufacturing services to pharmaceutical and biotechnology companies, announced a strategic growth transaction of more than $200 million. And Bain Capital Life Sciences led the deal while existing investor Vivo Capital remains a key shareholder in the company.
This partnership will support Serán’s continued growth by building a new commercial-scale manufacturing facility that will enable the company to provide integrated capabilities across multiple drug delivery and final dose formats, enabling and accelerated solutions for clients from early development to commercial supply.
This new facility will be completed in 2026 and will support oral, pulmonary, and nasal delivery modalities with commercial-scale particle engineering solutions, including spray drying, hot melt extrusion, nano-milling, and fluid-bed manufacturing, and comprehensive finished dose capabilities including granulation, tableting, coating, encapsulation, powder filling, including for modified release products. Plus, an adjacent facility (already under construction) will enable extensive packaging, labeling, serialization, and distribution capabilities.
Serán has 200+ team members, of which more than 150 are scientists and engineers. As the build-out progresses, Serán will hire as many as 150 additional employees, resulting in the creation of a nearly 200,000-square-foot campus in Bend, Oregon.
KEY QUOTES:
“This transaction is a significant milestone in Serán’s evolution, which will enable us to rapidly scale our clinical manufacturing capability to support launches of new medicines, as well as serve new clients seeking state-of-the-art commercial capacity. We are proud to have the additional support and resources of a preeminent life sciences investor in Bain Capital who shares our vision for expanding Serán’s science-based drug development capabilities to enable commercial manufacturing of complex medicines.”
-Dan Smithey, Co-Founder and CEO of Serán
“We are impressed with Serán’s differentiated expertise and capabilities in drug development and clinical manufacturing. We believe the Company is well-positioned to benefit from long-term secular tailwinds given the importance of drug delivery technology to help address increasing challenges facing next generation oral drugs. Dan and his talented team have an exceptional track record of growing technology-driven CDMO businesses in the solubility solution space. We look forward to an impactful partnership and to leveraging our experience and resources to build and scale Serán into a true end-to-end provider of manufacturing services for complex drug products.”
-Will Cozean, a Managing Director at Bain Capital
“We have been impressed by the accomplishments Dan and the team at Serán have achieved during our partnership thus far, and we are excited to partner with both Serán and Bain as the company advances in its next stage of development to expand into commercial-scale projects to serve pharma innovators in advancing their products to markets and patients worldwide.”
-Gaurav Aggarwal, a Managing Partner at Vivo Capital
